22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed an agreement with The Sheba Fund for Health Services and Research, Chaim Sheba Medical Center…
Race Oncology's Mr Phil Lynch (CEO & MD) and Dr Daniel Tillett (CSO & ED) presented to the MST Access Australian Micro & Small Caps Conference 2021 on the 17th…
Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in IsraelTrialog Clinical Trials Ltd to supply trial drugs and provide…
Race CEO/MD Phillip Lynch speaks to the Australia Shareholders Association about Race Oncology and our Three Pillar strategy to commercialise Bisantrene.
Contract Research Organisation Parexel has been appointed to support an Australian trial of Bisantrene in Acute Myeloid Leukemia (AML) patients with extramedullary diseaseThe study led by Associate Professor Anoop Enjeti…
